



**S-8921** 

Catalog No: tcsc0015040

| Available Sizes  |  |
|--|--|
| Size: 1mg  |  |
| Size: 5mg  |  |
| Size: 10mg   |  |
| Specifications   |  |
| CAS No:<br>151165-96-7                                     |  |
| Formula:<br>C <sub>30</sub> H <sub>36</sub> O <sub>9</sub> |  |
| Pathway:<br>Others   |  |
| Target:<br>Others  |  |
| Purity / Grade: >98%                                       |  |
| Solubility:<br>10 mM in DMSO                               |  |
| Observed Molecular Weight:<br>540.6                        |  |
|  |  |

## **Product Description**

S-8921 is an ileal Na<sup>+</sup>/bile acid cotransporter (**IBAT**) inhibitor.

IC50 & Target: IBAT<sup>[1]</sup>

In Vitro:





S-8921 is an ileal Na<sup>+</sup>/bile acid cotransporter (IBAT) inhibitor. S-8921 inhibits the uptake velocity of 60  $\mu$ M [<sup>3</sup>H] taurocholate dose-dependently in IBAT-COS cells, and the IC<sub>50</sub> value of S-8921 is 66±8  $\mu$ M<sup>[1]</sup>.

*In Vivo:* Seven-day treatment with S-8921 causes a dramatic decrease of serum cholesterol concentrations in hamsters. The hypocholesterolemic effects of S-8921 are dose-dependent, but S-8921 does not affect body weight. An increase of fecal bile acid excretion is observed especially at higher doses of S-8921<sup>[1]</sup>. S-8921 treatment for 1 to 2 weeks causes a decrease in serum total cholesterol concentrations, with 0.01% S-8921 (4.0 to 4.6 mg/kg) being almost maximally effective<sup>[2]</sup>.

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!